Salipro DirectMX™ Enables Discovery of Novel Therapeutics Against GPCRs

Time: 10:00 am
day: Day Two

Details:

  • Introduction to the Salipro DirectMX™ technology
  • How to use the Salipro technology in antibody discovery, structure biology and for development of small molecular compounds
  • The chemokine receptor CXCR4 is a validated oncology target, and the development of new compounds has been hampered by difficulties purifying the native receptor
  • Showcasing Salipro DirectMX™ for CXCR4, its characterization, and the Cryo-EM structure determination of the native human wildtype CXCR4

Speakers: